Abdulmaged Traish's research while affiliated with University of Massachusetts Boston and other places
What is this page?
This page lists the scientific contributions of an author, who either does not have a ResearchGate profile, or has not yet added these contributions to their profile.
It was automatically created by ResearchGate to create a record of this author's body of work. We create such pages to advance our goal of creating and maintaining the most comprehensive scientific repository possible. In doing so, we process publicly available (personal) data relating to the author as a member of the scientific community.
If you're a ResearchGate member, you can follow this page to keep up with this author's work.
If you are this author, and you don't want us to display this page anymore, please let us know.
It was automatically created by ResearchGate to create a record of this author's body of work. We create such pages to advance our goal of creating and maintaining the most comprehensive scientific repository possible. In doing so, we process publicly available (personal) data relating to the author as a member of the scientific community.
If you're a ResearchGate member, you can follow this page to keep up with this author's work.
If you are this author, and you don't want us to display this page anymore, please let us know.
Publications (402)
There has been little recognition within the medical community of the health impact of testosterone (T) deficiency (TD), also known as hypogonadism, and the substantial benefits of testosterone therapy (TTh) on health and quality of life despite high-level clinical evidence. In a roundtable symposium, investigators summarized the contemporary evide...
Introduction
There still seem to be controversies regarding the effectiveness of testosterone therapy (TTh) on erectile function. There is limited information as to the duration of treatment required to achieve maximum effect. Hackett et al. have suggested that erectile function improves up to 3.8 years in men with hypogonadism and diabetes receivi...
Introduction
Erectile dysfunction (ED) is common in men with obesity and hypogonadism. We have previously shown long-term testosterone therapy (TTh) to result in improved erectile function and reductions in waist circumference (WC) and weight in obese men with hypogonadism with different etiologies. The FDA advises against treating hypogonadism in...
Introduction
Erectile dysfunction affects nearly two-thirds of all men with type 2 diabetes mellitus (T2DM), in whom it is approximately 3.5 times more prevalent, has greater severity, and is less responsive to phosphodiesterase-5 (PDE5) inhibitors than in men without diabetes (Fonseca et al. Diabetologia 2004;47:1914–1923). Long-term testosterone...
Introduction
While beneficial effects of testosterone therapy (TTh) on erectile function (EF) are well established, there is limited information about the duration of TTh required to achieve maximum effects. Hackett et al. demonstrated that EF kept improving for 3.8 years in men with hypogonadism and type 2 diabetes receiving continuous TTh (World...
In women, androgens not only serve as precursors for biosynthesis of estrogens but also exert a critical physiological role in sexual function, bone health, mood, behavior, and cognition. Despite research in the 1940s establishing the physiological role of testosterone (T) in women's health and the substantial benefits of T therapy (TTh) in women,...
Introduction
Guidelines by the ESC and EASD recommend that patients with hypertension and type 2 diabetes (T2DM) are treated individually to a systolic blood pressure (SBP) target of <130 mmHg. There is little information in the literature about effects of testosterone therapy on blood pressure in men with hypogonadism and T2DM.
Methods
In a regis...
Introduction
Guidelines by the ESC and EASD state that patients with diabetes have a two-fold excess risk of vascular outcomes. An increasing number of studies suggests that testosterone therapy (TTh) has cardiometabolic benefits in men with hypogonadism and type 2 diabetes (T2DM).
Methods
In a registry of men with hypogonadism in a urological off...
More men died of COVID-19 than women, suggesting estrogens may protect women. However, COVID-19 deaths among men and women were inconsistent among countries throughout the world. Genetics, epigenetics and inborn errors of immunity may account for the disparity in mortality among men and women with COVID-19 than sex steroid hormones.
Aim
To provide a clinical practice guideline for the use of testosterone including identification of patients, laboratory testing, dosing, post-treatment monitoring, and follow-up care in women with hypoactive sexual desire disorder (HSDD).
Methods
The International Society for the Study of Women's Sexual Health appointed a multidisciplinary panel...
Background
The Global Consensus Position Statement on the Use of Testosterone Therapy for Women (Global Position Statement) recommended testosterone therapy for postmenopausal women with hypoactive sexual desire disorder (HSDD).
Aim
To provide a clinical practice guideline for the use of testosterone including identification of patients, laborator...
Background:
The Global Consensus Position Statement on the Use of Testosterone Therapy for Women (Global Position Statement) recommended testosterone therapy for postmenopausal women with hypoactive sexual desire disorder (HSDD).
Aim:
To provide a clinical practice guideline for the use of testosterone including identification of patients, laborat...
Background
Cardiovascular safety of testosterone therapy (TTh) in men with functional hypogonadism has been debated.
Purpose
To investigate cardiovascular risk factors and incidence of major adverse cardiovascular events (MACE) and mortality in a high-risk population in a real-world setting.
Methods
Of 773 men with functional (non-organic) hypogo...
Aims:
Type 2 diabetes mellitus (T2DM) is a public health threat. Men with T2DM often exhibit hypogonadism. We investigated whether testosterone therapy (TTh) in men with hypogonadism and T2DM improves glycemic control, insulin sensitivity and results in remission of T2DM.
Material and methods:
356 men who had total testosterone (T) ≤12.1 nmol/L...
5α-dihydrotestosterone (5α-DHT) is the most potent natural androgen. 5α-DHT elicits a multitude of physiological actions, in
a host of tissues, including prostate, seminal vesicles, hair follicles, skin, kidney, and lacrimal and meibomian glands. However,
the physiological role of 5α-DHT in human physiology, remains questionable and, at best, poorl...
Post-finasteride syndrome (PFS) is a constellation of serious adverse side effects manifested in clinical symptoms that develop and persist in patients during and/or after discontinuing finasteride treatment in men with pattern hair loss (androgenetic alopecia) or benign prostatic hyperplasia. These serious adverse side effects include persistent o...
Introduction:
Although healthy young men demonstrate diurnal pattern of serum testosterone (T), minimal information is available regarding diurnal variation in young men with T deficiency.
Methods:
Blood samples were obtained over a 24-hour period at 08:00, 11:00, 14:00, 17:00, 20:00, and 08:00 the following morning. Men were categorized as norm...
Introduction:
The International Consultation for Sexual Medicine met in Lisbon in 2018 to review updated recommendations regarding testosterone deficiency (TD) and its treatment.
Aim:
To provide updated clinical recommendations regarding TD and its treatment.
Methods:
A Medline search was performed for testosterone (T) articles published since...
Background: Weight loss in obese subjects is notoriously difficult to achieve through lifestyle interventions, and even harder to maintain long-term. Testosterone therapy has shown promising results in long-term but not short-term studies. Material and Methods: In an observational registry study of 805 men with hypogonadism in a urological office,...
Introduction and Objective Longterm data of Testosterone (T) substitution in hypogonadal men are scarce and clinical value of this treatment is especially debated in men with functional (so called “late-onset”) hypogonadism. A long-term registry comprising various groups of patients provides an efficient tool to approach this issue. Methods Registr...
Background: Quality of life in men is influenced by general health, sexual function and urinary function. These components are associated with both weight and inflammatory status. Material and Methods: 805 men with hypogonadism are enrolled in a registry study in a urological office. 412 received TTh with TU 1000 mg/12 weeks (T-group) while 393 opt...
Background: Effects of testosterone on lipid patterns are inconsistent. While in short-term studies, testosterone usually lowers HDL, long-term studies seem to increase HDL. Total cholesterol, LDL and triglycerides are either reduced by TTh, or effects are neutral. Effects of TTh on lipids may depend on treatment duration. Material and Methods: In...
Background: The prevalence of hypogonadism in men with hypertension is high and may be related to overweight and obesity. In an ongoing registry study in a single urology practice, we monitored blood pressure and hemodynamic parameters for up to 12 years. Material and Methods: In a registry study of men with hypogonadism in a urological office, 676...
Background: Testosterone and its metabolite estradiol are essential factors in bone metabolism, and hypogonadism is an established risk factor for osteoporosis. Material and Methods: In a registry study of otherwise unselected men with hypogonadism in a urological office, 102 of 805 patients (13%) had osteoporosis diagnosed and treated elsewhere. 6...
Background: 3 studies reported an increased cardiovascular risk with TTh while hundreds of studies have demonstrated cardiovascular benefits of TTh in men with hypogonadism. Material and Methods: A prospective, cumulative registry study to investigate long-term effectiveness and safety of depot TU to treat hypogonadism was established in 2004 in a...
The role of testosterone in the pathophysiology of inflammation is of critical clinical importance; however, no universal mechanism(s) has been advanced to explain the complex and interwoven pathways of androgens in the attenuation of the inflammatory processes. PubMed and EMBASE searches were performed, including the following key words: “testoste...
Purpose of Review
Post-finasteride syndrome (PFS) is a disorder characterized by a set of clinical symptoms experienced during use or after drug discontinuation. This cluster of symptoms encompasses overall sexual dysfunction (SD), erectile dysfunction (ED), loss of libido, depression, suicidal ideation, anxiety, panic attacks, insomnia, and cognit...
Introduction:
Many studies have reported that 5α-reductase inhibitors (finasteride and dutasteride) raise serum testosterone (T) levels, yet there is lack of consistency among studies on this point.
Aim:
To review and meta-analyze available studies reporting changes in serum T concentrations in men treated with 5α-reductase inhibitors (5α-RIs)....
Lower urinary tract function is modulated by neural, vascular and urethral and bladder structural elements. The pathophysiological mechanisms of lower urinary tract symptoms (LUTS) encompass prostate enlargement, alterations in urethra histological structure bladder fibrosis and alterations in pelvic neuronal and vascular networks, The complex path...
Objective:
The objective of this consensus document is to broaden the perspective on clinical management of genitourinary syndrome of menopause to include androgens.
Methods:
A modified Delphi method was used to reach consensus among the 14 international panelists representing multiple disciplines and societies.
Results:
Menopause-related geni...
Introduction:
Genitourinary conditions in women increase in prevalence with age. Androgens are prerequisite hormones of estrogen biosynthesis, are produced in larger amounts than estrogens in women, and decrease throughout adulthood. However, research and treatment for genitourinary complaints have traditionally focused on estrogens to the exclusi...
Introduction:
Testosterone therapy has been controversial since its synthesis in the 1930s to the present day. Testosterone's history provides depth and context for current controversies.
Aim:
To review the history of testosterone therapy from its initial synthesis in the 1930s to the modern day.
Methods:
Expert review of the literature.
Main...
Objective:
A label change for testosterone (T) products in March 2015 followed a highly-publicized FDA advisory committee meeting in September 2014. Changes included a warning of possible increased cardiovascular (CV) risks and restriction of indicated populations to younger men with a limited set of known etiologies of testosterone deficiency (TD...
Androgens are steroid hormones with pleotropic and diverse biochemical and physiological functions, and androgen deficiency exerts a negative impact on human health. Testosterone (T) either directly or via its transformation into the more potent metabolite 5α-dihydrotestosterone (5α-DHT) or via aromatization into estradiol (E2) modulates important...
Introduction:
Testosterone (T) deficiency (TD; hypogonadism) has deleterious effects on men's health; negatively affects glycometabolic and cardiometabolic functions, body composition, and bone mineral density; contributes to anemia and sexual dysfunction; and lowers quality of life. T therapy (TTh) has been used for the past 8 decades to treat TD...
Objectives:
To investigate the effects of long-term testosterone (T) therapy (TTh) on urinary and sexual functions and quality of life (QoL) in hypogonadal men.
Patients and methods:
Observational, prospective, cumulative registry study in 656 men (age: 60.7 ± 7.2 years) with total T levels ≤12.1 nmol/L and symptoms of hypogonadism. In the T-tre...
Background
Dutasteride has been successfully used in treatment of lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH). However, dutasteride inhibits 5α-reductase type 1 and type 2 enzymes and may compromises glucocorticoids and androgen metabolism and alters metabolic function resulting in undesirable metabolic and s...
Objectives:
In the absence of large, prospective, placebo-controlled studies of longer duration, substantial evidence regarding the safety and risk of testosterone (T) therapy (TTh) with regard to cardiovascular (CV) outcomes can only be gleaned from observational studies. To date, there are limited studies comparing the effects of long-term TTh i...
Frailty is a clinical condition related to changes in metabolism, to sarcopenia, and to decline in muscle mass and strength, bone mineral density, and physical function with aging. The pathophysiology of frailty is multifactorial and associated with comorbidities. Testosterone is implicated in regulating metabolic functions, maintenance of muscle a...
Conference on the development of the international expert consensus to address frequently asked questions related to a medical condition of testosterone deficiency (TD, male hypogonadism) and testosterone therapy was held in Prague (Czech Republic) on October 1, 2015. The included experts were representatives from a variety of medical specialties,...
Although testosterone therapy in men with testosterone deficiency was introduced in the early 1940s, utilization of this effective
treatment approach in hypogonadal men is met with considerable skepticism and resistance. Indeed, for decades, the fear that testosterone
may cause prostate cancer has hampered clinical progress in this field. Neverthel...